Invention Grant
- Patent Title: Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
-
Application No.: US15508229Application Date: 2015-09-17
-
Publication No.: US11279771B2Publication Date: 2022-03-22
- Inventor: Helle Heibroch Petersen , Berit Olsen Krogh , Jens Breinholt , Mikael Kofod-Hansen , Ida Hilden
- Applicant: Novo Nordisk A/S
- Applicant Address: DK Bagsvaerd
- Assignee: Novo Nordisk A/S
- Current Assignee: Novo Nordisk A/S
- Current Assignee Address: DK Bagsvaerd
- Agent Rosemarie R. Wilk-Orescan
- Priority: EP14185138 20140917
- International Application: PCT/EP2015/071359 WO 20150917
- International Announcement: WO2016/042093 WO 20160324
- Main IPC: C07K16/38
- IPC: C07K16/38 ; A61K39/00
Abstract:
The application discloses bispecific TFPI antibodies that are capable of specifically and simultaneously binding two epitopes within TFPI (1-161). Such bispecific antibodies strongly enhance thrombin generation by neutralising TFPI, even where the concentration of TFPI is elevated. Bispecific antibodies of the invention or compositions comprising them may be used for the treatment of subjects with a coagulopathy.
Public/Granted literature
- US20170260289A1 ANTIBODIES CAPABLE OF BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR (1-161) Public/Granted day:2017-09-14
Information query
